NCT04504916

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Condition: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

Business reasons